FCH
AVXL icon

Freestone Capital Holdings’s Anavex Life Sciences AVXL Stock Holding History

Freestone Capital Holdings’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-20,000
Closed -$178K – 562
2025
Q3 		$178K Hold
20,000
– – 0.01% 513
2025
Q2 		$184K Hold
20,000
– – 0.01% 434
2025
Q1 		$172K Hold
20,000
– – 0.01% 428
2024
Q4 		$215K Hold
20,000
– – 0.01% 416
2024
Q3 		$114K Buy
20,000
+6,200
+45% +$35.8K ﹤0.01% 422
2024
Q2 		$58.2K Hold
13,800
– – ﹤0.01% 452
2024
Q1 		$70.2K Hold
13,800
– – ﹤0.01% 433
2023
Q4 		$128K Hold
13,800
– – 0.01% 383
2023
Q3 		$90.4K Buy
13,800
+3,800
+38% +$30.2K ﹤0.01% 356
2023
Q2 		$81.3K Buy
+10,000
New +$85.7K ﹤0.01% 370

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
NL
NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Freestone Capital Holdings's AVXL Position: Q4 2025 in Review

Freestone Capital Holdings sold out of Anavex Life Sciences (AVXL) in Q4 2025, closing a stake of 20,000 shares — an estimated $178K sold.

Freestone Capital Holdings first reported a position in AVXL in Q2 2023 and held it in 10 quarters. The position peaked at $215K in Q4 2024. 184 funds tracked by Wall St. Rank hold AVXL as of Q4 2025.

  • Freestone Capital Holdings reported no remaining Anavex Life Sciences position as of Q4 2025 after selling out during the quarter.
  • Freestone Capital Holdings sold 20,000 Anavex Life Sciences shares in Q4 2025, an estimated $178K.
  • Freestone Capital Holdings first reported a position in Anavex Life Sciences in Q2 2023 and held it in 10 quarters.
  • Freestone Capital Holdings's Anavex Life Sciences position peaked at $215K in Q4 2024.
  • 184 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2025.

Based on Freestone Capital Holdings's 13F filing for Q4 2025, filed 23 Jan 2026.